Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a global provider of spinal fusion
technologies, announced today financial results for the third
quarter ended September 30, 2015.
- Third quarter consolidated net revenues of $43 million.
- Third quarter adjusted EBITDA of $5.3 million, 12.2% of
revenue.
- Stabilized U.S. business - revenue of $27.4 million, up
sequentially from the second quarter of 2015.
Highlights of the Third quarter 2015 and
Recent Activities
Positive Progress Made Towards Alphatec’s
Corporate Strategic Objectives
Financial
- Consolidated revenues of $43.0 million as reported, or $45.7
million in constant currency.
- Consolidated revenues were impacted by $2.7 million of foreign
currency headwinds.
- International revenues grew 13.2% in constant currency over the
third quarter of 2014 and represent 36% of global revenues as
reported.
Strategic Pillar #1: “Go-to-Market”
Product Portfolio and R&D Pipeline
- Arsenal CBX™ successfully used in over 50 patients during
limited market release and on track to enter full commercial launch
by year-end.
- Battalion™ titanium-coated PEEK interbody fusion system
introduced in the U.S. and first surgical cases have been
successfully completed.
- Alphatec Neocore™ Osteoconductive Matrix, a synthetic scaffold
for the regeneration of bone, was successfully launched and first
surgical case completed.
- Arsenal™ Deformity and lateral development programs remain on
track for Q1 2016 introduction.
Strategic Pillar #2: Transform
Manufacturing and Distribution Operations
- Outsourcing of manufacturing to drive reductions in instrument
costs, implant unit costs and capital expense on track - estimating
completion by January 2016.
- Partnered with UPS for outsourcing physical distribution of
implant and instrument sets to enhance customer service and drive
set utilization improvements - staged rollout underway.
Strategic Pillar #3: Expand Global
Commercial Participation
- Significant commercial expansion in large metropolitan markets
continues through direct selling reps, distributor relationships,
new surgeon customers and new geographies.
- Anticipate at least $3.0 million of revenue from these new
markets in the U.S. in Q4 2015.
“Q3 marks a turning point for Alphatec where we
are beginning to see early results from our overall company
transformation,” said Jim Corbett, President and Chief Executive
Officer of Alphatec Spine. “First of all, our competitive
product portfolio and pipeline is stronger than it has ever
been. Second, we remain on schedule with improving our
underlying cost structure by outsourcing both manufacturing and
distribution. And, now, our commercial transformation is
well-underway and gaining momentum both in the U.S. and
internationally and we expect that to continue into Q4 and
2016. Through the execution of each of our strategic pillars,
we are building a stronger, more competitive company – one that we
believe is poised to gain share and generate profitable growth in
the future.”
Quarter Ended September 30,
2015
Consolidated net revenues for the third quarter
of 2015 were $43.0 million as reported, down 15.7% compared to
$51.0 million reported for the third quarter of 2014, or down 10.4%
on a constant currency basis. Consolidated revenues were
impacted by $2.7 million in the third quarter due to declines in
the valuation of the Japanese Yen and Euro against the U.S.
Dollar.
U.S. net revenues for the third quarter of 2015
were $27.4 million, down 21.3%, compared to $34.8 million reported
for the third quarter of 2014.
International net revenues for the third quarter
of 2015 were $15.6 million, down 3.7% compared to $16.2 million for
the third quarter of 2014, or up 13.2% on a constant currency
basis.
Consolidated gross profit and gross margin for
the third quarter of 2015 were $28.5 million and 66.2%,
respectively, compared to $36.3 million and 71.2%, respectively,
for the third quarter of 2014.
Gross profit declined 21.6% from the third
quarter of 2014 primarily as a result of lower U.S. sales volume,
foreign currency translation effects and global geographic mix.
Gross margin declined 5.0 percentage points
compared to a strong quarter for gross margin in third quarter
2014. The decline over prior year is primarily attributable
to unfavorable variation in global regional and product mix, as
well as currency effects, and lower milestones and royalties in the
third quarter 2014.
Total operating expenses for the third quarter
of 2015 were $193.4 million, reflecting an increase of $158.9
million compared to the third quarter of 2014. This variance
is driven primarily by non-cash, goodwill and intangible asset
impairment charges totaling $165.2 million and restructuring
expenses totaling $335 thousand, offset by savings in R&D and
G&A functions, as well as lower commission expenses as a result
of lower U.S. sales volume. The Company is required to test
for goodwill impairment according to specific accounting standards
annually, or on an interim basis in the case of specific
circumstances. Due to the decline of the Company’s market
capitalization during the third quarter, the Company was required
to perform a valuation of its goodwill and intangible assets, which
resulted in a $165.2 million non-cash impairment charge. As
this is a non-cash charge, this does not affect the ongoing
operations of the Company.
When adjusted for non-recurring impairment,
restructuring and IPR&D expenses, total operating expenses for
the third quarter of 2015 would be $27.6 million, reflecting an
improvement of 18.7%, or approximately $6.4 million, compared to
the third quarter of 2014, and an improvement of 9.2% sequentially.
GAAP net loss for the third quarter of 2015 was
$160.3 million or ($1.61) per share (basic and diluted), compared
to a net loss of $3.0 million, or ($0.03) per share basic and
($0.04) diluted for the third quarter of 2014. GAAP net loss
for Q3 was unfavorably impacted by $165.2 million of non-cash
impairment charges, as well as favorable $6.3 million of warrant
fair-value adjustments attributable to our underlying stock
price. Non-GAAP EPS, when adjusted for the non-cash, goodwill
impairment charges and restructuring expenses, was ($0.00) per
share (basic), compared to ($0.1) per share (basic) for the third
quarter of 2014.
Adjusted EBITDA in the third quarter of 2015 was
$5.3 million, or 12.2% of revenues, compared to $8.2 million, or
16.1% of revenues reported in the third quarter of 2014.
Third quarter 2015 adjusted EBITDA represents net income excluding
effects of interest, taxes, depreciation, amortization, stock-based
compensation and other non-recurring expense items such as
in-process research and development expense, asset impairments and
restructuring expenses.
Cash and cash equivalents were $10.5 million at
September 30, 2015, compared to $8.9 million reported at June 30,
2015. Additionally, the Company has reported $3.5 million of
restricted cash, which must be used for future payment obligations
associated with the Orthotec settlement.
2015 Financial Guidance
“In the third quarter we continued to
execute on our overall corporate transformation and we are very
encouraged by the recent progress we’ve made in our commercial
expansion efforts, especially in the U.S.,” said Mike O’Neill,
Alphatec Spine’s Chief Financial Officer. “We believe
that the efforts we are making there will help provide a path for
future growth for us. That said, we recognize that our
revenues for the first nine months of 2015 were softer than we
anticipated. Accordingly we are revising our full-year
guidance for revenue and adjusted EBITDA. Looking
forward, we view 2015 as a building year where we are laying the
foundation for us to evolve and strengthen our position in the
global spinal market.”
Based on currently prevailing exchange rates,
the Company is adjusting full year 2015 revenue guidance to
approximately $188.7 million on an as-reported basis.
Additionally, the Company expects annual adjusted EBITDA to be
approximately $22 million in 2015.
Conference Call
Alphatec Spine will webcast its Quarterly Update
Call today at 5:00 p.m. EDT / 2:00 p.m. PDT. Jim Corbett,
President and CEO of Alphatec Spine, will lead the call.
During the call the Company plans to provide further details
underlying its third quarter 2015 financial results.
To access the webcast, please log on to
www.alphatecspine.com approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. For those without access to the internet, the live
call may be accessed by phone by calling toll-free (877) 556-5251
(U.S. / Canada) or (720) 545-0036 (international), participant
passcode number 60386444. A replay of the call will also be
available on the investor relations section of Alphatec Spine's
website for at least 30 days.
Non-GAAP Information
Alphatec Spine reports certain non-GAAP
financial measures such as non-GAAP earnings and earnings per
share, adjusted for effects of amortization and other non-recurring
or expense items, such as impairments, loss on extinguishment of
debt, and restructuring expenses. Adjusted EBITDA included in
this press release is a non-GAAP financial measure that represents
net income (loss) excluding the effects of interest, taxes,
depreciation, amortization, stock-based compensation expenses, in
process research and development (IPR&D) expenses and other
non-recurring income or expense items, such as impairments,
restructuring expenses, severance expenses, litigation expenses,
damages associated with ongoing litigation and transaction-related
expenses. The Company believes that non-GAAP adjusted EBITDA
provides investors with an additional tool for evaluating the
Company's core performance, which management uses in its own
evaluation of continuing operating performance, and a base-line for
assessing the future earnings potential of the Company. For
completeness, management uses non-GAAP adjusted EBITDA in
conjunction with GAAP earnings and earnings per common share
measures. These non-GAPP financial measures should be
considered in addition to, and not as a substitute for, or superior
to, financial measures calculated in accordance with GAAP.
Included below are reconciliations of the non-GAAP
financial measures to the comparable GAAP financial measure.
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary
of Alphatec Holdings, Inc., is a global medical device company that
designs, develops, manufactures and markets spinal fusion
technology products and solutions for the treatment of spinal
disorders associated with disease and degeneration, congenital
deformities and trauma. The Company's mission is to improve lives
by delivering advancements in spinal fusion technologies. The
Company and its affiliates market products in the U.S. and
internationally via a direct sales force and independent
distributors.
Additional information can be found at
www.alphatecspine.com.
Forward Looking Statements
This press release may contain "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Alphatec Spine cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward looking statements include the references to
Alphatec Spine's 2015 revenue guidance and 2015 adjusted EBITDA
guidance; the success of the Company's initiatives to drive global
sales growth and expand its geographical sales coverage, including
without limitation the Company’s ability to realize $3.0 million in
new revenues in the fourth quarter of 2015 based on the Company’s
U.S. sales expansion efforts, increase margins and increase
operating efficiencies; and the success of the Company in achieving
its three strategic pillars, and the Company’s ability to implement
a plan that will ensure that it competes more effectively in the
marketplace, expands global participation, and improves operations
through the Company’s plan to outsource manufacturing and
distribution. The important factors that could cause actual
operating results to differ significantly from those expressed or
implied by such forward-looking statements include, but are not
limited to: the uncertainty of success in developing new
products or products currently in Alphatec Spine's pipeline,
including the products discussed in this press release; the
uncertainties in the Company’s ability to execute upon its
strategic operating plan to outsource manufacturing and
distribution; the uncertainties regarding the ability to
successfully license or acquire new products, and the commercial
success of such products; failure to achieve acceptance of Alphatec
Spine's products by the surgeon community, including Battalion,
Alphatec Neocore, Arsenal Deformity and Arsenal CBX; failure to
successfully implement outsourcing, streamlining and lean
activities to create anticipated savings; failure to obtain FDA
clearance or approval or international regulatory approvals for new
products, including the products discussed in this press release,
or unexpected or prolonged delays in the process; continuation of
favorable third party payor reimbursement for procedures performed
using the Company’s products; unanticipated expenses or liabilities
or other adverse events affecting cash flow or the Company’s
ability to successfully control its costs or achieve profitability;
uncertainty of additional funding; the Company’s ability to compete
with other competing products and with emerging new technologies;
product liability exposure; an unsuccessful outcome in any
litigation in which the Company is a defendant; patent infringement
claims; claims related to the Company’s intellectual property and
the Company’s ability to meet its financial obligations under its
credit agreements and the Orthotec settlement agreement. The words
“believe,” “will,” “should,” “expect,” “intend,” “estimate” and
“anticipate,” variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement.
Please refer to the risks detailed from time to time in Alphatec
Spine's SEC reports, including its Annual Report Form 10-K for the
year ended December 31, 2014, filed on February 27, 2015 with the
Securities and Exchange Commission, as well as other filings on
Form 10-Q and periodic filings on Form 8-K. Alphatec Spine
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
ALPHATEC HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
(in thousands, except
per share amounts - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
$ |
42,996 |
|
|
$ |
51,013 |
|
|
|
$ |
138,276 |
|
|
$ |
153,353 |
|
|
|
Cost of revenues |
|
14,154 |
|
|
|
14,272 |
|
|
|
|
48,234 |
|
|
|
46,305 |
|
|
|
Amortization of
acquired intangible assets |
|
363 |
|
|
|
435 |
|
|
|
|
1,093 |
|
|
|
1,328 |
|
|
|
Total cost of
revenues |
|
14,517 |
|
|
|
14,707 |
|
|
|
|
49,327 |
|
|
|
47,633 |
|
|
|
Gross profit |
|
28,479 |
|
|
|
36,306 |
|
|
|
|
88,949 |
|
|
|
105,720 |
|
|
|
|
|
66.2 |
% |
|
|
71.2 |
% |
|
|
|
64.3 |
% |
|
|
68.9 |
% |
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
Research and
development |
|
1,898 |
|
|
|
4,423 |
|
|
|
|
9,661 |
|
|
|
13,138 |
|
|
|
In-process
research and development |
|
274 |
|
|
|
527 |
|
|
|
|
274 |
|
|
|
527 |
|
|
|
Sales and
marketing |
|
17,134 |
|
|
|
18,649 |
|
|
|
|
51,973 |
|
|
|
56,545 |
|
|
|
General and
administrative |
|
8,094 |
|
|
|
10,213 |
|
|
|
|
26,473 |
|
|
|
33,676 |
|
|
|
Amortization of
acquired intangible assets |
|
521 |
|
|
|
742 |
|
|
|
|
1,867 |
|
|
|
2,257 |
|
|
|
Impairment of
goodwill and intangibles |
|
165,171 |
|
|
|
- |
|
|
|
|
165,171 |
|
|
|
- |
|
|
|
Restructuring
expenses |
|
335 |
|
|
|
20 |
|
|
|
|
163 |
|
|
|
706 |
|
|
|
Total operating
expenses |
|
193,427 |
|
|
|
34,574 |
|
|
|
|
255,582 |
|
|
|
106,849 |
|
|
|
Operating income
(loss) |
|
(164,948 |
) |
|
|
1,732 |
|
|
|
|
(166,633 |
) |
|
|
(1,129 |
) |
|
|
Interest and
other income (expense), net |
|
2,966 |
|
|
|
(4,801 |
) |
|
|
|
(2,702 |
) |
|
|
(10,532 |
) |
|
|
Pretax net loss |
|
(161,982 |
) |
|
|
(3,069 |
) |
|
|
|
(169,335 |
) |
|
|
(11,661 |
) |
|
|
Income tax
(benefit) provision |
|
(1,717 |
) |
|
|
(28 |
) |
|
|
|
(562 |
) |
|
|
948 |
|
|
|
Net loss |
$ |
(160,265 |
) |
|
$ |
(3,041 |
) |
|
|
$ |
(168,773 |
) |
|
$ |
(12,609 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net loss per
share |
$ |
(1.61 |
) |
|
$ |
(0.03 |
) |
|
|
$ |
(1.70 |
) |
|
$ |
(0.13 |
) |
|
|
Diluted net loss per
share |
$ |
(1.61 |
) |
|
$ |
(0.04 |
) |
|
|
$ |
(1.70 |
) |
|
$ |
(0.13 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares
- basic |
|
99,376 |
|
|
|
97,391 |
|
|
|
|
99,258 |
|
|
|
97,040 |
|
|
|
Weighted-average shares
- diluted |
|
99,376 |
|
|
|
98,329 |
|
|
|
|
99,258 |
|
|
|
97,258 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
(in thousands -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
|
2015 |
|
|
|
2014 |
|
|
ASSETS |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash
equivalents |
$ |
10,502 |
|
|
$ |
19,735 |
|
|
Restricted
Cash |
|
3,450 |
|
|
|
4,400 |
|
|
Accounts
receivable, net |
|
36,252 |
|
|
|
40,440 |
|
|
Inventories,
net |
|
42,328 |
|
|
|
41,747 |
|
|
Prepaid expenses
and other current assets |
|
5,225 |
|
|
|
5,466 |
|
|
Deferred income
tax assets |
|
2,518 |
|
|
|
1,324 |
|
|
Total current
assets |
|
100,275 |
|
|
|
113,112 |
|
|
|
|
|
|
|
|
|
|
|
Property and equipment,
net |
|
23,720 |
|
|
|
26,040 |
|
|
Goodwill |
|
- |
|
|
|
171,333 |
|
|
Intangibles, net |
|
22,943 |
|
|
|
30,259 |
|
|
Other assets |
|
1,446 |
|
|
|
4,179 |
|
|
Total assets |
$ |
148,384 |
|
|
$ |
344,923 |
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' (DEFICIT)
EQUITY |
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
Accounts
payable |
$ |
10,827 |
|
|
$ |
10,130 |
|
|
Accrued
expenses |
|
27,216 |
|
|
|
35,393 |
|
|
Deferred
revenue |
|
831 |
|
|
|
1,300 |
|
|
Common stock
warrant liabilities |
|
687 |
|
|
|
8,702 |
|
|
Current portion
of long-term debt |
|
59,018 |
|
|
|
8,076 |
|
|
Total current
liabilities |
|
98,579 |
|
|
|
63,601 |
|
|
|
|
|
|
|
|
|
|
|
Total long term
liabilities |
|
52,356 |
|
|
|
108,765 |
|
|
Redeemable
preferred stock |
|
23,603 |
|
|
|
23,603 |
|
|
Stockholders'
(deficit) equity |
|
(26,154 |
) |
|
|
148,954 |
|
|
Total liabilities and
stockholders' (deficit) equity |
$ |
148,384 |
|
|
$ |
344,923 |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
RECONCILIATION OF NON-GAAP FINANCIAL
MEASURES |
|
(in thousands, except per share amounts -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
(loss), as reported |
$ |
(164,948 |
) |
|
$ |
1,732 |
|
|
|
$ |
(166,633 |
) |
|
$ |
(1,129 |
) |
|
|
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
3,440 |
|
|
|
2,895 |
|
|
|
|
9,067 |
|
|
|
9,247 |
|
|
|
Amortization of
intangible assets |
|
188 |
|
|
|
379 |
|
|
|
|
2,072 |
|
|
|
1,174 |
|
|
|
Amortization of
acquired intangible assets |
|
884 |
|
|
|
1,177 |
|
|
|
|
2,960 |
|
|
|
3,585 |
|
|
|
Total EBITDA |
|
(160,436 |
) |
|
|
6,183 |
|
|
|
|
(152,534 |
) |
|
|
12,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add back significant
items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation |
|
(78 |
) |
|
|
1,502 |
|
|
|
|
2,440 |
|
|
|
3,641 |
|
|
|
In-process
research and development |
|
274 |
|
|
|
527 |
|
|
|
|
274 |
|
|
|
527 |
|
|
|
Goodwill and
intangible impairment |
|
165,171 |
|
|
|
- |
|
|
|
|
165,171 |
|
|
|
- |
|
|
|
Litigation
settlement and trial costs |
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
|
4,779 |
|
|
|
Restructuring
and other charges |
|
335 |
|
|
|
20 |
|
|
|
|
163 |
|
|
|
742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA, as adjusted for
significant items |
$ |
5,266 |
|
|
$ |
8,232 |
|
|
|
$ |
15,514 |
|
|
$ |
22,566 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, as
reported |
$ |
(160,265 |
) |
|
$ |
(3,041 |
) |
|
|
$ |
(168,773 |
) |
|
$ |
(12,609 |
) |
|
|
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
acquired intangible assets |
|
884 |
|
|
|
1,177 |
|
|
|
|
2,960 |
|
|
|
3,585 |
|
|
|
Amortization of
intangible assets |
|
188 |
|
|
|
379 |
|
|
|
|
2,072 |
|
|
|
1,174 |
|
|
|
In-process
research and development |
|
274 |
|
|
|
527 |
|
|
|
|
274 |
|
|
|
527 |
|
|
|
Goodwill and
intangible impairment |
|
165,171 |
|
|
|
- |
|
|
|
|
165,171 |
|
|
|
- |
|
|
|
Litigation
settlement and trial costs |
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
|
4,779 |
|
|
|
Restructuring
and other charges |
|
335 |
|
|
|
20 |
|
|
|
|
163 |
|
|
|
742 |
|
|
|
Warrant fair
value adjustment |
|
(6,299 |
) |
|
|
(513 |
) |
|
|
|
(8,015 |
) |
|
|
292 |
|
|
|
|
|
|
|
|
|
|
|
|
|
. |
|
|
|
|
|
|
|
|
Net income (loss), as
adjusted for significant items |
$ |
288 |
|
|
$ |
(1,451 |
) |
|
|
$ |
(6,148 |
) |
|
$ |
(1,510 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common
share - basic |
$ |
(1.61 |
) |
|
$ |
(0.03 |
) |
|
|
$ |
(1.70 |
) |
|
$ |
(0.13 |
) |
|
|
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
acquired intangible assets |
|
0.01 |
|
|
|
0.01 |
|
|
|
|
0.03 |
|
|
|
0.04 |
|
|
|
Amortization of
intangible assets |
|
0.00 |
|
|
|
0.00 |
|
|
|
|
0.02 |
|
|
|
0.01 |
|
|
|
In-process
research and development |
|
0.00 |
|
|
|
0.01 |
|
|
|
|
0.00 |
|
|
|
0.01 |
|
|
|
Goodwill and
intangible impairment |
|
1.66 |
|
|
|
- |
|
|
|
|
1.66 |
|
|
|
- |
|
|
|
Litigation
settlement and trial costs |
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
|
0.05 |
|
|
|
Restructuring
and other charges |
|
0.00 |
|
|
|
0.00 |
|
|
|
|
0.00 |
|
|
|
0.01 |
|
|
|
Warrant fair
value adjustment |
|
(0.06 |
) |
|
|
(0.01 |
) |
|
|
|
(0.08 |
) |
|
|
0.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common
share - basic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
as adjusted for
significant items |
$ |
0.00 |
|
|
$ |
(0.01 |
) |
|
|
$ |
(0.06 |
) |
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares
- basic |
|
99,376 |
|
|
|
97,391 |
|
|
|
|
99,258 |
|
|
|
97,040 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
|
|
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES
AND GROSS PROFIT |
|
|
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
% Change |
|
|
|
September 30, |
|
% Change |
|
% Change |
|
Foreign |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
As Reported |
|
Operations |
|
Currency |
|
|
|
|
|
|
|
|
Revenues by geographic
segment |
|
|
|
|
|
U.S. |
$ |
27,385 |
|
|
$ |
34,808 |
|
|
|
-21.3 |
% |
|
|
-21.3 |
% |
|
|
0.0 |
% |
|
|
International |
|
15,611 |
|
|
|
16,205 |
|
|
|
-3.7 |
% |
|
|
13.2 |
% |
|
|
-16.8 |
% |
|
|
Total revenues |
$ |
42,996 |
|
|
$ |
51,013 |
|
|
|
-15.7 |
% |
|
|
-10.4 |
% |
|
|
-5.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit by
geographic segment |
|
|
|
|
|
U.S. |
$ |
19,035 |
|
|
$ |
26,378 |
|
|
|
International |
|
9,444 |
|
|
|
9,928 |
|
|
|
Total gross profit |
$ |
28,479 |
|
|
$ |
36,306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit margin by
geographic segment |
|
|
|
|
|
U.S. |
|
69.5 |
% |
|
|
75.8 |
% |
|
|
International |
|
60.5 |
% |
|
|
61.3 |
% |
|
|
Total gross profit
margin |
|
66.2 |
% |
|
|
71.2 |
% |
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
% Change |
|
|
|
September 30, |
|
% Change |
|
% Change |
|
Foreign |
|
|
|
|
2015 |
|
|
|
2014 |
|
|
As Reported |
|
Operations |
|
Currency |
|
|
|
|
|
|
|
|
Revenues by geographic
segment |
|
|
|
|
|
U.S. |
$ |
85,099 |
|
|
$ |
101,376 |
|
|
|
-16.1 |
% |
|
|
-16.1 |
% |
|
|
0.0 |
% |
|
|
International |
|
53,177 |
|
|
|
51,977 |
|
|
|
2.3 |
% |
|
|
20.5 |
% |
|
|
-18.2 |
% |
|
|
Total revenues |
$ |
138,276 |
|
|
$ |
153,353 |
|
|
|
-9.8 |
% |
|
|
-3.7 |
% |
|
|
-6.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit by
geographic segment |
|
|
|
|
|
U.S. |
$ |
56,602 |
|
|
$ |
74,210 |
|
|
|
International |
|
32,347 |
|
|
|
31,510 |
|
|
|
Total gross profit |
$ |
88,949 |
|
|
$ |
105,720 |
|
|
|
|
|
|
|
|
|
Gross profit margin by
geographic segment |
|
|
|
|
|
U.S. |
|
66.5 |
% |
|
|
73.2 |
% |
|
|
International |
|
60.8 |
% |
|
|
60.6 |
% |
|
|
Total gross profit
margin |
|
64.3 |
% |
|
|
68.9 |
% |
|
|
|
Footnotes: |
|
|
1)
The impact from foreign currency represents the percentage change
in 2015 revenues due to the change in foreign |
|
|
exchange rates for the
periods presented. |
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
(in thousands, except
per share amounts - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2015 |
|
|
|
|
|
|
Non-GAAP |
|
|
|
|
|
|
GAAP |
|
Adjustments |
|
Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
$ |
42,996 |
|
|
$ |
- |
|
|
$ |
42,996 |
|
|
|
|
Cost of revenues |
|
14,154 |
|
|
|
- |
|
|
|
14,154 |
|
|
|
|
Amortization of
acquired intangible assets |
|
363 |
|
|
|
- |
|
|
|
363 |
|
|
|
|
Total cost of
revenues |
|
14,517 |
|
|
|
- |
|
|
|
14,517 |
|
|
|
|
Gross profit |
|
28,479 |
|
|
|
- |
|
|
|
28,479 |
|
|
|
|
|
|
66.2 |
% |
|
|
|
|
66.2 |
% |
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Research and
development |
|
1,898 |
|
|
|
- |
|
|
|
1,898 |
|
|
|
|
In-process
research and development |
|
274 |
|
|
|
(274 |
) |
|
|
- |
|
|
|
|
Sales and
marketing |
|
17,134 |
|
|
|
- |
|
|
|
17,134 |
|
|
|
|
General and
administrative |
|
8,094 |
|
|
|
- |
|
|
|
8,094 |
|
|
|
|
Amortization of
acquired intangible assets |
|
521 |
|
|
|
- |
|
|
|
521 |
|
|
|
|
Impairment of
goodwill and intangibles |
|
165,171 |
|
|
|
(165,171 |
) |
|
|
- |
|
|
|
|
Restructuring
expenses |
|
335 |
|
|
|
(335 |
) |
|
|
- |
|
|
|
|
Total operating
expenses |
|
193,427 |
|
|
|
(165,780 |
) |
|
|
27,647 |
|
|
|
|
Operating loss |
|
(164,948 |
) |
|
|
165,780 |
|
|
|
832 |
|
|
|
|
Interest and
other income (expense), net |
|
2,966 |
|
|
|
- |
|
|
|
2,966 |
|
|
|
|
Loss from continuing
operations before taxes |
|
(161,983 |
) |
|
|
165,780 |
|
|
|
3,798 |
|
|
|
|
Income tax
benefit |
|
(1,717 |
) |
|
|
- |
|
|
|
(1,717 |
) |
|
|
|
Net loss |
$ |
(160,265 |
) |
|
$ |
165,780 |
|
|
$ |
5,515 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2015 |
|
|
|
|
|
|
Non-GAAP |
|
|
|
|
|
|
GAAP |
|
Adjustments |
|
Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
$ |
138,276 |
|
|
$ |
- |
|
|
$ |
138,276 |
|
|
|
|
Cost of revenues |
|
48,234 |
|
|
|
- |
|
|
|
48,234 |
|
|
|
|
Amortization of
acquired intangible assets |
|
1,093 |
|
|
|
- |
|
|
|
1,093 |
|
|
|
|
Total cost of
revenues |
|
49,327 |
|
|
|
- |
|
|
|
49,327 |
|
|
|
|
Gross profit |
|
88,949 |
|
|
|
- |
|
|
|
88,949 |
|
|
|
|
|
|
64.3 |
% |
|
|
|
|
64.3 |
% |
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Research and
development |
|
9,661 |
|
|
|
- |
|
|
|
9,661 |
|
|
|
|
In-process
research and development |
|
274 |
|
|
|
(274 |
) |
|
|
- |
|
|
|
|
Sales and
marketing |
|
51,973 |
|
|
|
- |
|
|
|
51,973 |
|
|
|
|
General and
administrative |
|
26,473 |
|
|
|
- |
|
|
|
26,473 |
|
|
|
|
Amortization of
acquired intangible assets |
|
1,867 |
|
|
|
- |
|
|
|
1,867 |
|
|
|
|
Transaction
related costs |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
Impairment of
goodwill and intangibles |
|
165,171 |
|
|
|
(165,171 |
) |
|
|
- |
|
|
|
|
Restructuring
expenses |
|
163 |
|
|
|
(163 |
) |
|
|
- |
|
|
|
|
Total operating
expenses |
|
255,582 |
|
|
|
(165,608 |
) |
|
|
89,974 |
|
|
|
|
Operating loss |
|
(166,633 |
) |
|
|
165,608 |
|
|
|
(1,025 |
) |
|
|
|
Interest and
other income (expense), net |
|
(2,702 |
) |
|
|
- |
|
|
|
(2,702 |
) |
|
|
|
Loss from continuing
operations before taxes |
|
(169,335 |
) |
|
|
165,608 |
|
|
|
(3,727 |
) |
|
|
|
Income tax
benefit |
|
(562 |
) |
|
|
- |
|
|
|
(562 |
) |
|
|
|
Net loss |
$ |
(168,773 |
) |
|
$ |
165,608 |
|
|
$ |
(3,165 |
) |
|
|
|
|
|
|
|
|
|
|
|
CONTACT: Investor/Media Contact:
Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024